FDA Places Pamrevlumab for DMD on Fast Track

FDA Places Pamrevlumab for DMD on Fast Track

291665

FDA Places Pamrevlumab for DMD on Fast Track

The U.S. Food and Drug Administration has granted fast track designation to pamrevlumab, an investigational treatment for Duchenne muscular dystrophy (DMD). The designation is given to medications that have the potential to treat serious conditions and to fill an unmet medical need. The designation allows the therapy’s developer, FibroGen, to have more frequent meetings with the FDA throughout the development process. The ultimate goal is to make effective therapies available to the public more quickly. The decision…

You must be logged in to read/download the full post.